TEAM (Thiotepa, Etoposide, Cytarabine, Melphalan) as conditioning regimen for lymphoma treatment with autologous haematopoietic stem cell transplantation

被引：0
|
作者：
Carella, A. M. [1 ]
Palumbo, G. [2 ]
Greco, M. M. [1 ]
Merla, E. [1 ]
Dell'Olio, M. [1 ]
Pisapia, G. [3 ]
Mazza, P. [3 ]
Ferrara, F. [4 ]
Musto, P. [5 ]
Rana, A. [6 ]
Guarini, A. [6 ]
Di Tonno, P. [7 ]
Pastore, D. [8 ]
D'Elia, M. [8 ]
Specchia, G. [8 ]
Capalbo, S. [2 ]
Cascavilla, N. [1 ]
机构：
[1] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[2] United Hosp, Foggia, Italy
[3] Hosp G Moscati, Taranto, Italy
[4] Hosp Cardarelli, Naples, Italy
[5] CROB, Rionero In Vulture, Italy
[6] IRCCS Canc Inst, Bari, Italy
[7] Hosp Di Venere, Bari, Italy
[8] Univ Hematol, Bari, Italy
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [11] Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)
    Jae-Cheol Jo
    Jin Seok Kim
    Je-Hwan Lee
    Jung-Hee Lee
    Sung-Nam Lim
    Sang Min Lee
    Sung-Soo Yoon
    In-Ho Kim
    Sung Hwa Bae
    Yoo Jin Lee
    Yunsuk Choi
    Won-Sik Lee
    Bone Marrow Transplantation, 2020, 55 : 1466 - 1468
  • [12] BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
    Wu, Ran
    Ma, Liyuan
    CELL TRANSPLANTATION, 2023, 32
  • [13] Autologous Stem Cell Transplantation with Bendaeam (Bendamustine, Etoposide, Cytarabine, Melphalan) As Conditioning Regimen for Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
    Garciaz, Sylvain
    Coso, Diane
    Broussais, Florence
    Schiano, Jean-Marc
    Calmels, Boris
    Saillard, Colombe
    Boudin, Lauris
    Amrane, Sophie
    Blaise, Didier
    Bouabdallah, Reda
    BLOOD, 2014, 124 (21)
  • [14] Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
    Frankiewicz, Andrzej
    Sadus-Wojciechowska, Maria
    Najda, Jacek
    Czerw, Tomasz
    Mendrek, Wlodzimierz
    Sobczyk-Kruszelnicka, Malgorzata
    Soska, Katarzyna
    Ociepa, Malgorzata
    Holowiecki, Jerzy
    Giebel, Sebastian
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2018, 22 (02): : 113 - 117
  • [15] High-dose etoposide, cytarabine and melphalan as conditioning regimen for autologous stem cell transplantation in patients with refractory or relapsed Hodgkin's lymphoma
    Bekadja, M. A.
    Osmani, S.
    Brahimi, M.
    Talhi, S.
    Bekadja, S.
    Belkhodja, S.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S446 - S446
  • [16] TEAM conditioning (Thiotepa, etoposide, cytarabine, melphalan) prior to autologous hematopoietic stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: First results from a prospective multicenter study
    Dulery, R.
    Lebras, L.
    Choquet, S.
    Amorim, S.
    Al Jijakli, A.
    Heuberger, L.
    Brissot, E.
    Battipaglia, G.
    Giannotti, F.
    Malard, F.
    Ruggeri, A.
    Sestili, S.
    Vekhoff, A.
    PCoppo
    Marjanovic, Z.
    Jaff, N.
    Corre, E.
    Lemonnier, M-P
    Belhocine, R.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S454 - S455
  • [17] TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study
    Dulery, Remy
    Lebras, Laure
    Choquet, Sylvain
    Di Blasi, Roberta
    AL Jijakli, Ahmad Kanj
    Heuberger, Laurence
    Brissot, Eolia
    Battipaglia, Giorgia
    Malard, Florent
    Mediavilla, Clemence
    Vekhoff, Anne
    Coppo, Paul
    Ledraa, Tounes
    Marjanovic, Zora
    Corre, Elise
    Lapusan, Simona
    Aoudjhane, Malek
    Belhocine, Ramdane
    Mohty, Mohamad
    BLOOD, 2019, 134
  • [18] TEAM conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) prior to autologous hematopoietic stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: first results from a prospective multicenter study
    Dulery, Remy
    Lebras, Laure
    Choquet, Sylvain
    Amorim, Sandy
    Al Jijakli, Ahmad
    Heuberger, Laurence
    Brissot, Eolia
    Battipaglia, Giorgia
    Giannotti, Federica
    Malard, Florent
    Ruggeri, Annalisa
    Mediavilla, Clemence
    Vekhoff, Anne
    Coppo, Paul
    Jaff, Nabaz
    Marjanovic, Zora
    Corre, Elise
    Lemonnier, Marie-Paule
    Belhocine, Ramdane
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2018, 53 : 618 - 618
  • [19] Outcomes of reduced dose team (thiotepa, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation for hodgkin and non-hodgkin lymphoma: A monocentric experience
    Marafioti, V.
    Barbato, S.
    Di Folca, S.
    Avilia, S.
    Grimaldi, F.
    Severino, A.
    Picardi, M.
    Luciano, L.
    Battipaglia, G.
    Pane, F.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 234 - 234
  • [20] Fotemustine, etoposide, aracyitin and melphalan. Variation of a "well tested" contitioning regimen for lymphoma treatment with autologous haematopoietic stem cell transplantation
    Scalone, R.
    Pinto, A.
    Marcacci, G.
    Cascavilla, N.
    Scalzulli, P.
    Di Renzo, N.
    Vergine, C.
    D'Arco, A.
    Crescimanno, A.
    Musso, M.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S251 - S251
12345